Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

MYD88 L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in CLL.

Improgo MR, Tesar B, Klitgaard JL, Magori-Cohen R, Yu L, Kasar S, Chaudhary D, Miao W, Fernandes SM, Hoang K, Westlin WF, Kim HT, Brown JR.

Br J Haematol. 2018 Dec 9. doi: 10.1111/bjh.15714. [Epub ahead of print]

PMID:
30537114
2.

Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma.

Lally JSV, Ghoshal S, DePeralta DK, Moaven O, Wei L, Masia R, Erstad DJ, Fujiwara N, Leong V, Houde VP, Anagnostopoulos AE, Wang A, Broadfield LA, Ford RJ, Foster RA, Bates J, Sun H, Wang T, Liu H, Ray AS, Saha AK, Greenwood J, Bhat S, Harriman G, Miao W, Rocnik JL, Westlin WF, Muti P, Tsakiridis T, Harwood HJ Jr, Kapeller R, Hoshida Y, Tanabe KK, Steinberg GR, Fuchs BC.

Cell Metab. 2019 Jan 8;29(1):174-182.e5. doi: 10.1016/j.cmet.2018.08.020. Epub 2018 Sep 20.

PMID:
30244972
3.

Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double-blind, crossover study.

Stiede K, Miao W, Blanchette HS, Beysen C, Harriman G, Harwood HJ Jr, Kelley H, Kapeller R, Schmalbach T, Westlin WF.

Hepatology. 2017 Aug;66(2):324-334. doi: 10.1002/hep.29246. Epub 2017 Jul 5.

4.

Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models.

Svensson RU, Parker SJ, Eichner LJ, Kolar MJ, Wallace M, Brun SN, Lombardo PS, Van Nostrand JL, Hutchins A, Vera L, Gerken L, Greenwood J, Bhat S, Harriman G, Westlin WF, Harwood HJ Jr, Saghatelian A, Kapeller R, Metallo CM, Shaw RJ.

Nat Med. 2016 Oct;22(10):1108-1119. doi: 10.1038/nm.4181. Epub 2016 Sep 19.

5.

Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats.

Harriman G, Greenwood J, Bhat S, Huang X, Wang R, Paul D, Tong L, Saha AK, Westlin WF, Kapeller R, Harwood HJ Jr.

Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):E1796-805. doi: 10.1073/pnas.1520686113. Epub 2016 Mar 14.

6.

Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.

Kelly PN, Romero DL, Yang Y, Shaffer AL 3rd, Chaudhary D, Robinson S, Miao W, Rui L, Westlin WF, Kapeller R, Staudt LM.

J Exp Med. 2015 Dec 14;212(13):2189-201. doi: 10.1084/jem.20151074. Epub 2015 Nov 30.

7.

Discovery of Clinical Candidate GSK1842799 As a Selective S1P1 Receptor Agonist (Prodrug) for Multiple Sclerosis.

Deng H, Bernier SG, Doyle E, Lorusso J, Morgan BA, Westlin WF, Evindar G.

ACS Med Chem Lett. 2013 Aug 27;4(10):942-7. doi: 10.1021/ml400194r. eCollection 2013 Oct 10.

8.

In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing.

Tjin Tham Sjin R, Lee K, Walter AO, Dubrovskiy A, Sheets M, Martin TS, Labenski MT, Zhu Z, Tester R, Karp R, Medikonda A, Chaturvedi P, Ren Y, Haringsma H, Etter J, Raponi M, Simmons AD, Harding TC, Niu D, Nacht M, Westlin WF, Petter RC, Allen A, Singh J.

Mol Cancer Ther. 2014 Jun;13(6):1468-79. doi: 10.1158/1535-7163.MCT-13-0966. Epub 2014 Apr 10.

9.

A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.

Eda H, Santo L, Cirstea DD, Yee AJ, Scullen TA, Nemani N, Mishima Y, Waterman PR, Arastu-Kapur S, Evans E, Singh J, Kirk CJ, Westlin WF, Raje NS.

Leukemia. 2014 Sep;28(9):1892-901. doi: 10.1038/leu.2014.69. Epub 2014 Feb 12.

PMID:
24518207
10.

Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans.

Evans EK, Tester R, Aslanian S, Karp R, Sheets M, Labenski MT, Witowski SR, Lounsbury H, Chaturvedi P, Mazdiyasni H, Zhu Z, Nacht M, Freed MI, Petter RC, Dubrovskiy A, Singh J, Westlin WF.

J Pharmacol Exp Ther. 2013 Aug;346(2):219-28. doi: 10.1124/jpet.113.203489. Epub 2013 May 24.

11.

Exploring amino acids derivatives as potent, selective, and direct agonists of sphingosine-1-phosphate receptor subtype-1.

Evindar G, Deng H, Bernier SG, Doyle E, Lorusso J, Morgan BA, Westlin WF.

Bioorg Med Chem Lett. 2013 Jan 15;23(2):472-5. doi: 10.1016/j.bmcl.2012.11.053. Epub 2012 Nov 27.

PMID:
23245510
12.

Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine.

Hagel M, Niu D, St Martin T, Sheets MP, Qiao L, Bernard H, Karp RM, Zhu Z, Labenski MT, Chaturvedi P, Nacht M, Westlin WF, Petter RC, Singh J.

Nat Chem Biol. 2011 Jan;7(1):22-4. doi: 10.1038/nchembio.492. Epub 2010 Nov 28.

PMID:
21113170
13.

Exploration of amino alcohol derivatives as novel, potent, and highly selective sphingosine-1-phosphate receptor subtype-1 agonists.

Evindar G, Bernier SG, Doyle E, Kavarana MJ, Satz AL, Lorusso J, Blanchette HS, Saha AK, Hannig G, Morgan BA, Westlin WF.

Bioorg Med Chem Lett. 2010 Apr 15;20(8):2520-4. doi: 10.1016/j.bmcl.2010.02.098. Epub 2010 Mar 3.

PMID:
20304639
14.

Synthesis and evaluation of arylalkoxy- and biarylalkoxy-phenylamide and phenylimidazoles as potent and selective sphingosine-1-phosphate receptor subtype-1 agonists.

Evindar G, Satz AL, Bernier SG, Kavarana MJ, Doyle E, Lorusso J, Taghizadeh N, Halley K, Hutchings A, Kelley MS, Wright AD, Saha AK, Hannig G, Morgan BA, Westlin WF.

Bioorg Med Chem Lett. 2009 Apr 15;19(8):2315-9. doi: 10.1016/j.bmcl.2009.02.073. Epub 2009 Feb 23.

PMID:
19282175
15.

Synthesis and evaluation of alkoxy-phenylamides and alkoxy-phenylimidazoles as potent sphingosine-1-phosphate receptor subtype-1 agonists.

Evindar G, Bernier SG, Kavarana MJ, Doyle E, Lorusso J, Kelley MS, Halley K, Hutchings A, Wright AD, Saha AK, Hannig G, Morgan BA, Westlin WF.

Bioorg Med Chem Lett. 2009 Jan 15;19(2):369-72. doi: 10.1016/j.bmcl.2008.11.072. Epub 2008 Nov 24.

PMID:
19081720
16.

An inhibitor of methionine aminopeptidase type-2, PPI-2458, ameliorates the pathophysiological disease processes of rheumatoid arthritis.

Lazarus DD, Doyle EG, Bernier SG, Rogers AB, Labenski MT, Wakefield JD, Karp RM, Clark EJ, Lorusso J, Hoyt JG, Thompson CD, Hannig G, Westlin WF.

Inflamm Res. 2008 Jan;57(1):18-27. doi: 10.1007/s00011-007-7075-5.

PMID:
18209961
17.

Discovery of +(2-{4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl}-cyclopropyl)acetic acid as potent and selective alphavbeta3 inhibitor: design, synthesis, and optimization.

Nagarajan SR, Lu HF, Gasiecki AF, Khanna IK, Parikh MD, Desai BN, Rogers TE, Clare M, Chen BB, Russell MA, Keene JL, Duffin T, Engleman VW, Finn MB, Freeman SK, Klover JA, Nickols GA, Nickols MA, Shannon KE, Steininger CA, Westlin WF, Westlin MM, Williams ML.

Bioorg Med Chem. 2007 May 15;15(10):3390-412. Epub 2007 Mar 13.

PMID:
17387018
18.

Suppression of inflammation and structural damage in experimental arthritis through molecular targeted therapy with PPI-2458.

Hannig G, Bernier SG, Hoyt JG, Doyle B, Clark E, Karp RM, Lorusso J, Westlin WF.

Arthritis Rheum. 2007 Mar;56(3):850-60.

19.

A novel methionine aminopeptidase-2 inhibitor, PPI-2458, inhibits non-Hodgkin's lymphoma cell proliferation in vitro and in vivo.

Cooper AC, Karp RM, Clark EJ, Taghizadeh NR, Hoyt JG, Labenski MT, Murray MJ, Hannig G, Westlin WF, Thompson CD.

Clin Cancer Res. 2006 Apr 15;12(8):2583-90.

20.

Synthesis of pyrazoles and isoxazoles as potent alpha(v)beta3 receptor antagonists.

Penning TD, Khilevich A, Chen BB, Russell MA, Boys ML, Wang Y, Duffin T, Engleman VW, Finn MB, Freeman SK, Hanneke ML, Keene JL, Klover JA, Nickols GA, Nickols MA, Rader RK, Settle SL, Shannon KE, Steininger CN, Westlin MM, Westlin WF.

Bioorg Med Chem Lett. 2006 Jun 15;16(12):3156-61. Epub 2006 Apr 18.

PMID:
16621534
21.

Inhibition of melanoma tumor growth by a pharmacological inhibitor of MetAP-2, PPI-2458.

Hannig G, Lazarus DD, Bernier SG, Karp RM, Lorusso J, Qiu D, Labenski MT, Wakefield JD, Thompson CD, Westlin WF.

Int J Oncol. 2006 Apr;28(4):955-63.

PMID:
16525646
22.

Methionine aminopeptidases type I and type II are essential to control cell proliferation.

Bernier SG, Taghizadeh N, Thompson CD, Westlin WF, Hannig G.

J Cell Biochem. 2005 Aug 15;95(6):1191-203.

PMID:
15962312
23.

A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis.

Bernier SG, Lazarus DD, Clark E, Doyle B, Labenski MT, Thompson CD, Westlin WF, Hannig G.

Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10768-73. Epub 2004 Jul 12.

24.

A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis.

Harms JF, Welch DR, Samant RS, Shevde LA, Miele ME, Babu GR, Goldberg SF, Gilman VR, Sosnowski DM, Campo DA, Gay CV, Budgeon LR, Mercer R, Jewell J, Mastro AM, Donahue HJ, Erin N, Debies MT, Meehan WJ, Jones AL, Mbalaviele G, Nickols A, Christensen ND, Melly R, Beck LN, Kent J, Rader RK, Kotyk JJ, Pagel MD, Westlin WF, Griggs DW.

Clin Exp Metastasis. 2004;21(2):119-28.

PMID:
15168729
25.

Functional overlap and cooperativity among alphav and beta1 integrin subfamilies during skin angiogenesis.

Perruzzi CA, de Fougerolles AR, Koteliansky VE, Whelan MC, Westlin WF, Senger DR.

J Invest Dermatol. 2003 Jun;120(6):1100-9.

26.

Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice.

Reinmuth N, Liu W, Ahmad SA, Fan F, Stoeltzing O, Parikh AA, Bucana CD, Gallick GE, Nickols MA, Westlin WF, Ellis LM.

Cancer Res. 2003 May 1;63(9):2079-87.

27.

Integrins as targets of angiogenesis inhibition.

Westlin WF.

Cancer J. 2001 Nov-Dec;7 Suppl 3:S139-43. Review.

PMID:
11779085
28.

Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles.

Anderson SA, Rader RK, Westlin WF, Null C, Jackson D, Lanza GM, Wickline SA, Kotyk JJ.

Magn Reson Med. 2000 Sep;44(3):433-9.

29.

Peptidomimetic antagonists of alphavbeta3 inhibit bone resorption by inhibiting osteoclast bone resorptive activity, not osteoclast adhesion to bone.

Carron CP, Meyer DM, Engleman VW, Rico JG, Ruminski PG, Ornberg RL, Westlin WF, Nickols GA.

J Endocrinol. 2000 Jun;165(3):587-98.

PMID:
10828842
30.

Characterization of spontaneous metastasis in an aggressive breast carcinoma model using flow cytometry.

Schmidt CM, Settle SL, Keene JL, Westlin WF, Nickols GA, Griggs DW.

Clin Exp Metastasis. 1999;17(6):537-44.

PMID:
10763921
31.

A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy.

Carron CP, Meyer DM, Pegg JA, Engleman VW, Nickols MA, Settle SL, Westlin WF, Ruminski PG, Nickols GA.

Cancer Res. 1998 May 1;58(9):1930-5.

32.

Leukocyte adhesion to vascular endothelium induces E-selectin linkage to the actin cytoskeleton.

Yoshida M, Westlin WF, Wang N, Ingber DE, Rosenzweig A, Resnick N, Gimbrone MA Jr.

J Cell Biol. 1996 Apr;133(2):445-55.

33.
35.

Clozapine. Comments by a Sandoz official.

Westlin WF.

Hosp Community Psychiatry. 1990 Aug;41(8):874-6. No abstract available.

PMID:
2119335
36.

Exaggerated renal thromboxane and prostaglandin release by angiotensin II in suprarenal aortic coarctation hypertension.

Miller MJ, McNeill H, Westlin WF, Carroll MA, McGiff JC.

Pharmacol Res. 1989 Mar-Apr;21(2):201-10.

PMID:
2748507
37.
38.

Renal prostaglandin efflux induced by vasopressin, dDAVP and arachidonic acid: contrasting profile and sites of release.

Miller MJ, Westlin WF, McNeill H, McGiff JC.

Clin Exp Pharmacol Physiol. 1986 Aug;13(8):577-84.

PMID:
3791710
39.

Compartmental prostaglandin release by angiotensin II and arginine-vasopressin in rabbit isolated perfused kidneys.

Miller MJ, Carrara MC, Westlin WF, McNeill H, McGiff JC.

Eur J Pharmacol. 1986 Jan 14;120(1):43-50.

PMID:
3456305
40.

Opacities and thioridazine.

Westlin WF.

Am J Psychiatry. 1983 May;140(5):658-9. No abstract available.

PMID:
6846614
41.

One method for the systematic evaluation of adverse drug experience data within a pharmaceutical firm.

Westlin WF, Cuddihy RV, Bursik RJ, Seifert BG, Koelle JG.

Methods Inf Med. 1977 Oct;16(4):240-70. No abstract available.

PMID:
927209
42.

Deferoxamine as a chelating agent.

Westlin WF.

Clin Toxicol. 1971 Dec;4(4):597-602. No abstract available.

PMID:
5164172
43.

Deferoxamine in the treatment of acute iron poisoning. Clinical experiences with 172 children.

Westlin WF.

Clin Pediatr (Phila). 1966 Sep;5(9):531-5. No abstract available.

PMID:
5911317
44.

Current status of the hemophilia problem.

WESTLIN WF Jr, MILLS SD, OWEN CA Jr.

Minn Med. 1958 Oct;41(10):705-10. No abstract available.

PMID:
13600248

Supplemental Content

Loading ...
Support Center